The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms

被引:11
作者
Belcic Mikic, Tanja [1 ,2 ]
Pajic, Tadej [3 ,4 ]
Zver, Samo [1 ,2 ]
Sever, Matjaz [1 ,2 ]
机构
[1] Univ Med Ctr Ljubljana, Dept Hematol, Zaloska 7, Ljubljana 1000, Slovenia
[2] Univ Ljubljana, Fac Med, Vrazov Trg 2, Ljubljana 1000, Slovenia
[3] Univ Med Ctr Ljubljana, Clin Inst Genom Med, Slajmerjeva 4, Ljubljana 1000, Slovenia
[4] Univ Maribor, Fac Med, Taborska Ul 8, Maribor 2000, Slovenia
关键词
calreticulin; chaperone; calcium; myeloproliferative neoplasm; diagnostics; thrombocythemia; artificial intelligence; TYROSINE KINASE JAK2; THROMBOPOIETIN RECEPTOR; MUTANT CALRETICULIN; ESSENTIAL THROMBOCYTHEMIA; ACTIVATING MUTATION; REFRACTORY-ANEMIA; POLYCYTHEMIA-VERA; MYELOFIBROSIS; SYSTEM; MPL;
D O I
10.3390/ijms22073371
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CALR mutations are a revolutionary discovery and represent an important hallmark of myeloproliferative neoplasms (MPN), especially essential thrombocythemia and primary myelofibrosis. To date, several CALR mutations were identified, with only frameshift mutations linked to the diseased phenotype. It is of diagnostic and prognostic importance to properly define the type of CALR mutation and subclassify it according to its structural similarities to the classical mutations, a 52-bp deletion (type 1 mutation) and a 5-bp insertion (type 2 mutation), using a statistical approximation algorithm (AGADIR). Today, the knowledge on the pathogenesis of CALR-positive MPN is expanding and several cellular mechanisms have been recognized that finally cause a clonal hematopoietic expansion. In this review, we discuss the current basis of the cellular effects of CALR mutants and the understanding of its implementation in the current diagnostic laboratorial and medical practice. Different methods of CALR detection are explained and a diagnostic algorithm is shown that aids in the approach to CALR-positive MPN. Finally, contemporary methods joining artificial intelligence in accordance with molecular-genetic biomarkers in the approach to MPN are presented.
引用
收藏
页数:16
相关论文
共 124 条
[1]  
ACCETTA R, 2019, INT, V42, P76, DOI DOI 10.1111/IJLH.13117
[2]  
AGARWAL R, 2017, BLOOD, V96, P725, DOI DOI 10.1007/S00277-017-2937-6
[3]  
AGUILERADIAZ A, 2020, NEW ENGL J MED, V15
[4]   Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation [J].
Araki, Marito ;
Yang, Yinjie ;
Imai, Misa ;
Mizukami, Yoshihisa ;
Kihara, Yoshihiko ;
Sunami, Yoshitaka ;
Masubuchi, Nami ;
Edahiro, Yoko ;
Hironaka, Yumi ;
Osaga, Satoshi ;
Ohsaka, Akimichi ;
Komatsu, Norio .
LEUKEMIA, 2019, 33 (01) :122-131
[5]   Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms [J].
Araki, Marito ;
Yang, Yinjie ;
Masubuchi, Nami ;
Hironaka, Yumi ;
Takei, Hiraku ;
Morishita, Soji ;
Mizukami, Yoshihisa ;
Kan, Shin ;
Shirane, Shuichi ;
Edahiro, Yoko ;
Sunami, Yoshitaka ;
Ohsaka, Akimichi ;
Komatsu, Norio .
BLOOD, 2016, 127 (10) :1307-1316
[6]   The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].
Arber, Daniel A. ;
Orazi, Attilio ;
Hasserjian, Robert ;
Thiele, Jurgen ;
Borowitz, Michael J. ;
Le Beau, Michelle M. ;
Bloomfield, Clara D. ;
Cazzola, Mario ;
Vardiman, James W. .
BLOOD, 2016, 127 (20) :2391-2405
[7]   Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation [J].
Badbaran, A. ;
Fehse, B. ;
Christopeit, M. ;
Aranyossy, T. ;
Ayuk, F. A. ;
Wolschke, C. ;
Kroeger, N. .
BONE MARROW TRANSPLANTATION, 2016, 51 (06) :872-873
[8]   Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development [J].
Balligand, Thomas ;
Achouri, Younes ;
Pecquet, Christian ;
Gaudray, Gilles ;
Colau, Didier ;
Hug, Eva ;
Rahmani, Yacine ;
Stroobant, Vincent ;
Plo, Isabelle ;
Vainchenker, William ;
Kralovics, Robert ;
Van den Eynde, Benoit J. ;
Defour, Jean-Philippe ;
Constantinescu, Stefan N. .
LEUKEMIA, 2020, 34 (02) :510-521
[9]  
BARBUI T, 2016, FRONT ONCOL, V91, P430, DOI DOI 10.1002/AJH.24288
[10]  
BARBUI T, 2011, ANN HEMATOL, V29, P3179, DOI DOI 10.1200/JCO.2010.34.5298